MedinCell receives funding for the second formulation phase of its 6-month injectable contraceptive
January 24, 2019
Previous PostMedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management
Next PostPublication of the 2019 Financial Calendar
